Sorrento Reports Submission of MAA to COFEPRIS for COVI-STIX Rapid Detection Test
Shots.
- The company has submitted MAA to COFEPRIS (the health regulatory authority for Mexico) for its COVI-STIX rapid diagnostic test to detect SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients
- The test provides results in 15min. with positive detection as quickly as 2min for patient samples with high viral load.
- Additionally- Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses- including COVI-GUARD- COVI-AMG- COVI-SHIELD- Gene-MAb- COVI-MSC and COVI-DROPS and diagnostic test solutions- including COVI-TRACK- COVI-STIX and COVI-TRAC
Ref: Sorrento | Image: Sorrento
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com